LFU Open Hardware
Self-experimentation

DIY biohacking: what could help, what could hurt

A summary of everything identified so far, written for someone deciding whether to build one of these and use it on themselves. It is deliberately blunt about the unknowns.

Bottom line. The published effect is reversal of cellular senescence, meaning arrested cells start dividing again and their telomeres lengthen. That is biologically remarkable and, of all rejuvenation strategies, it is the category with the highest theoretical cancer concern. There is no human safety data beyond a suspended 10-person pilot and an ongoing 20-person trial that has not reported. Anyone doing this is running an experiment on themselves with an unknown long-term risk, and should say so plainly rather than call it a wellness routine.

Why this is an attractive DIY target anyway

Technically within reach

  • The stimulus is weak (roughly 0.5–4 mW/cm², about a thousand times below therapeutic physiotherapy ultrasound), and the components are the same family as ultrasonic cleaners.
  • No drug, no injection, no import of a controlled substance. Nothing to swallow, and the exposure stops when you switch it off.
  • The intervention is dose-controllable and measurable: unlike a supplement, you can verify exactly what you delivered, with a hydrophone.
  • Parameters are published well enough to aim at, and the gaps are listed in open questions.

Scientifically useful

  • Nobody has independently replicated this. A calibrated open device plus shared data is a real contribution, whatever the result.
  • The commercial path (patents, clinics, "longevity spa" pricing) will likely make access expensive. An open design keeps the knowledge public.
  • Cheap, well-characterised hardware also enables the safety experiments nobody is publishing: does LFU also wake up damaged or oncogene-arrested cells?
  • It fits the biohack.it model: structured protocol plus biomarkers, published openly.

Potential benefits reported so far

All of these come from cells and mice from one group, plus anecdotal human examples inside a patent application. None is established in humans.

ClaimEvidence levelWhat it would mean for a self-experimenter
Senescent cells resume proliferation; senescence markers normalisein vitro, one labThe core mechanism, but not directly measurable in yourself
SASP (inflammatory secretions) suppressedin vitroPotentially measurable: IL-6, TNF-α, hs-CRP, GDF-15 and similar in blood
Physical performance in old mice 7–10× shammice, small groupsMeasurable proxies: grip strength, SPPB, TUG, 6-minute walk, VO₂
Senescence-marker burden in kidney and pancreas reducedmiceNot measurable at home; blood proxies only
Insulin resistance in aged diabetic micetested and failedThe paper that tested this found no improvement in glucose control, body composition or physical function — only a muscle transcriptome shift toward less inflammation
Lifespan extensionnot significant per groupNot testable by an individual
Osteoarthritis pain ↓ ~70%, diabetes symptoms ↓ ~75% (patent examples, single cases)anecdote in a patentTreat as marketing-grade evidence, not data
Warm-water immersion itself (the sham arm) improves sleep, mood, blood pressure, recoveryseparately establishedA real confounder: you may feel better from the bath, not the ultrasound

Potential risks

1 · Oncogenic risk the serious one

Senescence is, in part, a tumour-suppression mechanism: a cell with DNA damage or an activated oncogene is locked out of the cell cycle by p53–p21 and p16–RB. An intervention that releases that arrest, without repairing the underlying genome, removes a safety barrier. The published in-vitro phenotype includes cell-cycle re-entry, reduced γH2AX and nuclear p53, and longer telomeres — exactly the profile that raises the concern.

Arguments that it may be lower risk

  • The stimulus is weak, transient and mechanical, not genetic reprogramming.
  • The proposed pathway (Ca²⁺ → autophagy up, mTORC1 down) overlaps with well-known geroprotective mechanisms.
  • No tumours were found at autopsy in the treated mice.
  • Persistent senescent cells are themselves pro-tumourigenic via the SASP, so leaving them alone is not risk-free either.

Arguments that the risk is real and untested

  • The mouse groups were tiny (6–8) and the animals were already very old. Tumour latency in humans is years to decades.
  • Nobody has tested LFU on oncogene-induced or DNA-damage-induced senescent cells, the dangerous kinds.
  • Whether cells that resume dividing still carry their DNA damage is unknown, and whether their checkpoints still work is unknown.
  • The same group reports ultrasound killing tumour cells at the same frequency and only 12–18 dB higher pressure, and a separate 2025 study reports that mechanical PIEZO1 activation can prime cancer cells toward a more aggressive state. See the cancer branch.
  • Telomere lengthening is a two-edged sword: it is also a step most cancers need.

Our position: the in-vitro oncogenic-safety experiment is part of this project, not an afterthought, and nobody should treat whole-body immersion as routine before it exists. See the plan in biological feedback → safety monitoring and question E1 in open questions.

2 · Electrical risk immediate and lethal

3 · Hearing — the risk nobody mentions underrated

4 · Acoustic and thermal risk

5 · Biological uncertainties beyond cancer

6 · Measurement and self-deception

Who should not do this

Based on the UT trial criteria plus our own risk reading. This is a starting list to review with a physician, not a medical clearance.

House rules for this project

  1. Bench before body. Cells and calibration first, then the hand study with the other hand as control, then a limb bath, and whole-body immersion last, only with an electrical safety case.
  2. No unverified dose, no session. A build that has not passed the acceptance test produces data that are not worth having.
  3. Sham-controlled and pre-registered. Declare the protocol and the endpoints before starting; run a sham phase; publish the result whichever way it goes.
  4. Baseline first, and enough of it. At least 2–3 baseline blood draws and functional tests before the first session.
  5. Medical partner. Blood tests interpreted with a clinician; exclusion criteria reviewed; a stop rule written in advance.
  6. Nothing sold, nothing claimed. No kits for sale, no treatments, no therapeutic claims, no charging anyone for a session. See IP rights.
  7. Publish the negatives. Failed builds, bad calibrations and null results go on the site too.